Apellis Pharmaceuticals (NASDAQ:APLS) Trading Up 4.2%

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)’s share price traded up 4.2% on Friday . The company traded as high as $41.00 and last traded at $40.94. 42,345 shares changed hands during mid-day trading, a decline of 97% from the average session volume of 1,477,604 shares. The stock had previously closed at $39.29.

Analyst Ratings Changes

APLS has been the topic of several research analyst reports. The Goldman Sachs Group boosted their target price on Apellis Pharmaceuticals from $66.00 to $74.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Needham & Company LLC restated a “buy” rating and set a $85.00 price objective on shares of Apellis Pharmaceuticals in a report on Friday, August 9th. Wedbush increased their price objective on shares of Apellis Pharmaceuticals from $38.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday, August 9th. UBS Group dropped their target price on shares of Apellis Pharmaceuticals from $85.00 to $83.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Finally, HC Wainwright decreased their price target on shares of Apellis Pharmaceuticals from $92.00 to $83.00 and set a “buy” rating for the company in a report on Friday, August 2nd. Four equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $72.13.

Apellis Pharmaceuticals Stock Up 4.5 %

The business’s 50-day moving average is $37.87 and its 200-day moving average is $45.70. The company has a market capitalization of $4.98 billion, a price-to-earnings ratio of -11.86 and a beta of 0.88. The company has a quick ratio of 4.18, a current ratio of 5.08 and a debt-to-equity ratio of 1.73.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Thursday, August 1st. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.03. Apellis Pharmaceuticals had a negative return on equity of 138.32% and a negative net margin of 52.99%. The firm had revenue of $199.70 million for the quarter, compared to analyst estimates of $190.89 million. During the same period last year, the company earned ($1.02) earnings per share. Apellis Pharmaceuticals’s revenue for the quarter was up 110.2% compared to the same quarter last year. As a group, equities analysts predict that Apellis Pharmaceuticals, Inc. will post -1.28 earnings per share for the current year.

Insider Activity

In related news, Director A. Sinclair Dunlop sold 37,000 shares of the stock in a transaction on Friday, June 21st. The shares were sold at an average price of $39.24, for a total transaction of $1,451,880.00. Following the sale, the director now directly owns 136,998 shares of the company’s stock, valued at $5,375,801.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 6.80% of the company’s stock.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of APLS. M&T Bank Corp acquired a new stake in Apellis Pharmaceuticals in the fourth quarter valued at approximately $280,000. Charles Schwab Investment Management Inc. grew its stake in Apellis Pharmaceuticals by 2.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 904,409 shares of the company’s stock valued at $54,138,000 after acquiring an additional 25,052 shares during the period. Vanguard Personalized Indexing Management LLC purchased a new stake in Apellis Pharmaceuticals in the 4th quarter worth $281,000. Great Lakes Advisors LLC acquired a new position in Apellis Pharmaceuticals during the fourth quarter worth $12,461,000. Finally, Level Four Advisory Services LLC purchased a new position in Apellis Pharmaceuticals during the fourth quarter valued at $626,000. Hedge funds and other institutional investors own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).